Debra Richardson to Adult
This is a "connection" page, showing publications Debra Richardson has written about Adult.
Connection Strength
0.942
-
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers. Cancer. 2025 Jan 01; 131(1):e35680.
Score: 0.104
-
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022 08; 166(2):219-229.
Score: 0.087
-
Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. Am J Clin Oncol. 2018 08; 41(8):797-801.
Score: 0.067
-
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202.
Score: 0.065
-
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. Obstet Gynecol. 2016 Mar; 127(3):468-473.
Score: 0.057
-
Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. Gynecol Oncol. 2012 Oct; 127(1):43-6.
Score: 0.044
-
Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. Gynecol Oncol. 2012 Mar; 124(3):508-11.
Score: 0.042
-
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6.
Score: 0.034
-
CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecol Oncol. 2008 Nov; 111(2):233-6.
Score: 0.034
-
Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecol Oncol. 2008 Feb; 108(2):449-51.
Score: 0.032
-
Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006 Nov; 103(2):667-72.
Score: 0.029
-
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Jan 11; 13(1).
Score: 0.026
-
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892). Cancer Chemother Pharmacol. 2024 Dec 14; 95(1):4.
Score: 0.026
-
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 06; 185:202-211.
Score: 0.025
-
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370.
Score: 0.019
-
Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
Score: 0.019
-
Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? Gynecol Oncol. 2020 03; 156(3):568-574.
Score: 0.018
-
A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 03 01; 106(3):464-471.
Score: 0.018
-
The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience. Am J Clin Oncol. 2018 12; 41(12):1225-1230.
Score: 0.017
-
The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. Eur J Obstet Gynecol Reprod Biol. 2018 Apr; 223:108-112.
Score: 0.016
-
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
Score: 0.016
-
The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment. Gynecol Oncol. 2017 03; 144(3):586-591.
Score: 0.015
-
Factors influencing primary treatment of midline vulvar cancers. Gynecol Oncol. 2016 07; 142(1):133-138.
Score: 0.014
-
Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignancies. Brachytherapy. 2016 May-Jun; 15(3):341-346.
Score: 0.014
-
Ovarian involvement in endometrioid adenocarcinoma of uterus. Gynecol Oncol. 2015 Sep; 138(3):532-5.
Score: 0.014
-
Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent Urban Population. J Reprod Med. 2015 May-Jun; 60(5-6):243-8.
Score: 0.013
-
Adnexal masses requiring surgical intervention in women with advanced cervical cancer. Gynecol Oncol. 2014 Sep; 134(3):552-5.
Score: 0.013
-
Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. Gynecol Oncol. 2014 Jul; 134(1):84-9.
Score: 0.012
-
The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol Oncol. 2010 Aug 01; 118(2):172-5.
Score: 0.009
-
Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer. 2009 Oct; 19(7):1195-8.
Score: 0.009
-
Paratubal borderline serous tumors. Gynecol Oncol. 2009 Apr; 113(1):83-5.
Score: 0.009
-
Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol. 2009 Jan; 113(1):11-17.
Score: 0.009
-
Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Obstet Gynecol. 2008 Dec; 112(6):1207-1213.
Score: 0.009
-
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009 Jan; 112(1):55-9.
Score: 0.008